FGF2 Induces Resistance to Nilotinib through MAPK Pathway Activation in KIT Mutated Melanoma

FGF2 Induces Resistance to Nilotinib through MAPK Pathway Activation in KIT Mutated Melanoma

KIT is a bona fide oncogene in a subset of melanoma and, ex vivo, KIT inhibitors are very efficient at killing KIT-mutant melanoma cell lines. However, KIT-mutant melanoma tumors tend to show a de novo resistance in most cases and a limited duration of response when response is achieved. We performe...

Full description

Bibliographic Details
Main Authors: Pauline Tétu, Julie Delyon, Jocelyne André, Coralie Reger de Moura, Malak Sabbah, Ghanem E Ghanem, Maxime Battistella, Samia Mourah, Céleste Lebbé, Nicolas Dumaz
Format: Article
Language:English
Published: MDPI AG 2020-04-01
Series:Cancers
Subjects:
melanoma
targeted therapy resistance
KIT
MAPK
FGF2 BIM
Online Access:https://www.mdpi.com/2072-6694/12/5/1062

Internet

https://www.mdpi.com/2072-6694/12/5/1062

Similar Items